Regulatory TOPRA Webinar: Latest Regulatory Experiences
This year, our webinar centered on the challenges and opportunities associated with bringing novel medicinal products to market. No one in the...
Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.
1 min read
Veristat Blog : Published
The FDA and EMA offer expedited regulatory approval pathways to accelerate time-to-market for novel therapies intended to treat serious conditions and unmet medical needs. There are twelve special designations, many of which reduce clinical development and approval timelines. However, these are not always granted.
In this infographic, Veristat regulatory experts highlight the benefits of, qualifying criteria
for, and timing and procedures for twelve expedited programs and designations. Companies must build a strategic regulatory plan and leverage the right pathways to ensure a seamless regulatory strategy and submission plan for both U.S. and global registrations. Overall, these expedited regulatory pathways can save time and reduce the cost of bringing therapies to market—and to patients—sooner.
Download the infographic to learn more about the benefits of these key special designations:
Meet Veristat. Learn More.
This year, our webinar centered on the challenges and opportunities associated with bringing novel medicinal products to market. No one in the...
In this episode of Advancing Revolutionary Therapies, Kevin Hennegan, Director of Regulatory Affairs at Veristat, talks to Lisa Erickson, Sarah...
Learn about the impact of the new EU Medical Device Regulation (MDR) on the development of medical devices and drug-device combination products. Gain...